ARAnne Rullier

Anne Rullier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anne Rullier has a total of 151 co-authors. Here are the top co-authors by number of shared publications:

  • Christophe Laurent

    Departments of †Surgery

    4 shared publications
  • Eric Rullier

    Department of Colorectal Surgery, Haut-Lévêque Hospital, CHU Bordeaux, Bordeaux, France

    4 shared publications
  • Paulette Bioulac-Sage

    Department of Pathology, CHU Bordeaux

    4 shared publications
  • Brigitte Le Bail

    BRIC (BoRdeaux Institute of onCology), University of Bordeaux, Bordeaux, France

    3 shared publications
  • Véronique Vendrely

    Department of Radiotherapy, Haut-Lévêque Hospital, CHU Bordeaux, Bordeaux, France

    3 shared publications
  • A. Bardier

    Department of Pathology, CHU de La Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013, Paris, France

    2 shared publications

Latest Publications

  • Open Access

    What is the carbon footprint of a 100% digital pathology scenario in France?

    by Cyprien Tilmant, Alexis Trécourt, Constance Béchu, Brigitte Séroussi, Françoise Berthoud, Nicolas Perry, Clément Morand, Lucie Gaillot-Durand, Anne Rullier


  • Open Access

    Real-Time Characterization of Colonic Polyps: A Multicenter Prospective Study Evaluating the CAD-EYE System in Screening Colonoscopies

    by Marie Maigné, Maxime Saunier, Valentine Renaudeau, Xavier Dray, Antoine Guilloux, Elodie Cesbron-Métivier, Anne Olivier, Gabriel Rahmi, Guillaume Perrod, Elia Samaha, et al.

    INTRODUCTION: Polypectomy-related costs could potentially be reduced through optical diagnosis strategies, such as “diagnose-and-leave” and “resect-and-discard.” Artificial intelligence, using computer-aided diagnosis (CAD), may provide a reproducible optical diagnosis of colorectal lesions. This study aimed to assess the performance of the CAD-EYE system in the real-time characterization of colonic polyps. METHODS: We conducted a cross-sectional, multicenter study evaluating the CAD-EYE system in patients undergoing screening colonoscopies at 5 French centers. CAD-EYE predictions and assessments by endoscopists (hyperplastic vs neoplastic) were compared with histopathology results. The primary outcome was the sensitivity of CAD-EYE for predicting neoplastic polyps, compared with the predefined threshold of 85%. The secondary outcomes were the specificity, positive predictive value, negative predictive value, endoscopists' performance, and polyp detection rates. RESULTS: Of 398 polyps analyzed, 343 were included in the primary analysis. CAD-EYE characterization was feasible in 96% of cases. The sensitivity was 0.80 (95% confidence interval, 0.74–0.85), which failed to achieve the predefined threshold of 85% ( P = 0.064). The specificity, negative predictive value, and positive predictive value were 0.79, 0.64, and 0.90, respectively. Performance was higher for diminutive rectosigmoid polyps (DRSPs). Endoscopists showed higher sensitivity than CAD-EYE (0.90 vs 0.80, P = 0.001). CAD-EYE-assisted colonoscopies detected more polyps per procedure (3.3 vs 2.3, P < 0.001) than endoscopists alone. DISCUSSION: The performance of CAD-EYE was insufficient for the characterization of neoplastic colonic polyps. CAD-EYE performed better for DRSPs. AI seems to be beneficial for polyp detection.

  • Open Access

    Recycled formalin: a new tool to mitigate the environmental impact of surgical pathology in routine practice

    by Anne Rullier, Samuel Amintas, Maxime Marques, Brigitte Le Bail, Geneviève Belleannée, Pierre Dubus, Rémi Vergara, Noelle Bernard


  • CAP, comprendre, agir et partager : une boite à outils made in Nouvelle Aquitaine pour accompagner les établissements dans leur transformation écologique

    by Anne Rullier, Jérémy Guihenneuc, Sarah Ayraud-Thevenot, Bernard Jourdain, Léa Boissinot, Patricia Le Gonidec, Aude Deit, Claire Morisson, Cécile Andicoéchéa, Noëlle Bernard


  • Le formol recyclé : un nouvel outil d’atténuation de l’impact environnemental de l’ACP ?

    by Matthieu Chicaud, Rémi Vergara, Ivan Théate, Perrine Lesne, Anne Rullier, pour le Teap


  • Effects of neoadjuvant chemotherapy plus chemoradiotherapy on lymph nodes in rectal adenocarcinoma

    by Guillaume Chotard, Maylis Capdepont, Quentin Denost, Denis Smith, Véronique Vendrely, Eric Rullier, Anne Rullier

    The pathological nodal stage, determination of which requires examination of ≥ 12 lymph nodes, is one of the main prognostic factors in rectal cancer. Neoadjuvant chemoradiotherapy (CRT) may reduce the number of both lymph nodes retrieved and positive lymph nodes. Induction chemotherapy before CRT aimed at reducing the rate of distant metastases. However, the impact of this new treatment on number of lymph nodes retrieved and positive lymph nodes is unknown. This study was performed to evaluate the effects of neoadjuvant chemotherapy on lymph nodes in locally advanced rectal cancer treated by CRT. We retrospectively included patients with T2 – 4 Nx M0 rectal cancer and compared those receiving neoadjuvant chemotherapy plus CRT with those receiving CRT alone. From 2012 to 2019, 85 patients were treated with neoadjuvant chemotherapy + CRT and 189 with CRT alone. The number of lymph nodes retrieved (19 vs. 17, respectively, P = 0.434), the rate of specimens with ≥ 12 lymph nodes (92% vs. 88%, respectively, P = 0.397), and the median number of positive lymph nodes (1 vs. 2, respectively, P = 0.878) were similar between the two groups. However, the rate of pN0 was higher after neoadjuvant chemotherapy + CRT compared to CRT (75% vs. 62%, respectively, P = 0.030). Neoadjuvant chemotherapy before CRT for locally advanced rectal cancer did not modify the number of lymph nodes retrieved or the number of positive lymph nodes compared to CRT alone. However, it significantly increased the rate of tumors without any positive lymph nodes (ypN0).


  • National multicentric evaluation of quality of pathology reports for rectal cancer in France in 2016

    by C. Boutanos, M. Capdepont, M. Svrcek, F. Thélu, N. Guedj, F. Poizat, F. Bibeau, B. Turlin, A. Rousseau, A. Bardier, et al.

    The quality of pathologic assessment of rectal cancer specimens is crucial for treatment efficiency and survival. The Royal College of Pathologists (RCP) recommends evaluating the quality of the pathology report in routine practice using three quality indicators (QIs): the number of lymph nodes (LNs) analyzed (≥ 12), the rate of venous invasion (VI ≥ 30%), and peritoneal involvement (pT4a ≥ 10%). In this study, we evaluated the three QIs of the French national pathology reports and compared them with British guidelines and assessed the influence of neoadjuvant radiochemotherapy on QIs. From January 1 to December 31, 2016, all pathology reports for rectal adenocarcinoma were collected from French departments. Neoadjuvant radiochemotherapy included long-course radiotherapy with concomitant 5-FU-based chemotherapy. A total of 983 rectal cancer pathology reports were evaluated. A median of 15 LNs were analyzed and 81% of centers had ≥ 12 LNs. The rate of VI was 30% and 41% of centers had ≥ 30% VI. The rate of pT4a was 4% and 18% of centers reported ≥ 10% pT4a. None of the centers reached the threshold for the three QIs. All three QIs were lower after radiochemotherapy compared to surgery alone. In conclusion, in French routine practice, the values of two of the three QIs (LNs analyzed and VI) were globally in line with RCP guidelines. However, the rate of pT4a was very low, particularly after radiochemotherapy, suggesting its low value in rectal cancer.


  • Open Access

    Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22)

    by M. Karoui, A. Rullier, C. Mariette, E. Maillard, A. Bardier, F. Poizat, A. Luciani, A. Sarran, J.-L. Legoux, C. De Chaisemartin, et al.

    Background: Neoadjuvant chemotherapy has proven valuable in several tumors, but not in colon cancer (CC). The present randomized phase II trial addressed this issue in patients (pts) with locally advanced CC.


  • Open Access

    Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial

    by Mehdi Karoui, Anne Rullier, Alain Luciani, Franck Bonnetain, Marie-Luce Auriault, Antony Sarran, Geneviève Monges, Hervé Trillaud, Karine Le Malicot, Karen Leroy, et al.

    In patients with high risk stage II and stage III colon cancer (CC), curative surgery followed by adjuvant FOLFOX-4 chemotherapy has become the standard of care. However, for 20 to 30 % of these patients, the current curative treatment strategy of surgical excision followed by adjuvant chemotherapy fails either to clear locoregional spread or to eradicate distant micrometastases, leading to disease recurrence. Preoperative chemotherapy is an attractive concept for these CCs and has the potential to impact upon both of these causes of failure. Optimum systemic therapy at the earliest possible opportunity may be more effective at eradicating distant metastases than the same treatment given after the delay and immunological stress of surgery. Added to this, shrinking the primary tumor before surgery may reduce the risk of incomplete surgical excision, and the risk of tumor cell shedding during surgery. PRODIGE 22 - ECKINOXE is a multicenter randomized phase II trial designed to evaluate efficacy and feasibility of two chemotherapy regimens (FOLFOX-4 alone and FOLFOX-4 + Cetuximab) in a peri-operative strategy in patients with bulky CCs. Patients with CC deemed as high risk T3, T4 and/or N2 on initial abdominopelvic CT scan are randomized to either colectomy and adjuvant chemotherapy (control arm), or 4 cycles of neoadjuvant chemotherapy with FOLFOX-4 (for RAS mutated patients). In RAS wild-type patients a third arm testing FOLFOX+ cetuximab has been added prior to colectomy. Patients in the neoadjuvant chemotherapy arms will receive postoperative treatment for 4 months (8 cycles) to complete their therapeutic schedule. The primary endpoint of the study is the histological Tumor Regression Grade (TRG) as defined by Ryan. The secondary endpoints are: treatment strategy safety (toxicity, primary tumor related complications under chemotherapy, peri-operative morbidity), disease-free and recurrence free survivals at 3 years, quality of life, carcinologic quality and completeness of the surgery, initial radiological staging and radiological response to neoadjuvant chemotherapy, and the correlation between histopathological and radiological response. Taking into account a 50 % prevalence of CC without RAS mutation, accrual of 165 patients is needed for this Phase II trial. NCT01675999 (ClinicalTrials.gov)


  • Les cancers du bas rectum sont-ils de moins bon pronostic que ceux du moyen rectum ?

    by Anne Rullier, Marta Jarlier, Sophie Gourgou-Bourgade, Frédéric Bibeau, Catherine Chassagne, Christophe Hennequin, Philippe Étienne, Thierry Conroy, Jean-Pierre Gérard